Piper Sandler initiated coverage on Surgalign Holdings with a new price target
$SRGA
Industrial Specialties
Health Care
Piper Sandler initiated coverage of Surgalign Holdings with a rating of Overweight and set a new price target of $4.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/28/2021 | $1.50 | Buy → Hold | Craig Hallum |
15-12G - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its first quarter 2023 after the close of trading on May 11, 2023. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 437-3179 (U.S.) or 862-298-0702 (International). The webcast can be accessed through the investor relations section of Surgalign's website at www.surgalign.com/investors. A replay of the conference call will be available
Expands Xtant's Product Offering with the Leading PMA-Approved Intralaminar Stabilization Device Strengthens Surgalign's Balance Sheet as it Embarks on its Digital Health Strategy BELGRADE, Mont. and DEERFIELD, Ill., March 01, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, and Surgalign Holdings, Inc., (NASDAQ:SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced the completion of a transaction between the companies. On February 28, 2023, Xtant Medical and Surgalign entered
DEERFIELD, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2022 third quarter ended September 30, 2022. 2022 Third Quarter Corporate Highlights: Two new clinical sites in Ohio utilize the HOLO PortalTM surgical guidance system.FDA 510(k) clearance of the Cortera™ Spinal Fixation System, the first organically designed product by Surgalign.Expansion of the Fortilink® product portfolio with TiPlus™ technology products.Settlements with Resolve Surgical Technologies and RTI Surgical, Inc., and with
DEERFIELD, Ill., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of Paolo Amoruso as its new General Counsel and Corporate Secretary, effective August 1, 2022. He previously served as Interim General Counsel of Surgalign, having joined the Company in April 2022. Commenting on today's appointment, Terry Rich, President and Chief Executive Officer of Surgalign stated, "Paolo has been an invaluable member of our team since taking on the role of Interim General Counsel just a few months ago. He has quickly immersed
DEERFIELD, Ill., March 07, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ:SRGA) ("Surgalign"), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of David Lyle, as Chief Financial Officer, effective immediately. "David brings a wealth of experience in helping to guide the growth of technologies to Surgalign at an important and exciting inflection point of the company's evolution," said Terry Rich, Surgalign's president and chief executive officer. "David is joining Surgalign at a critical time as we transition to the early commercial stage of our HOLO AI technology platform, w
BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021. Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc. Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
DEERFIELD, Ill., June 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on June 22, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under chapter 11 of the U.S. Bankruptcy Code, the Company's securities will be delisted from The Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. As previously announced, Surgalign entered into an asset purchase agreement to
DEERFIELD, Ill., June 20, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) ("Surgalign" or the "Company") a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that the Company has entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors' hardware business outside of the U.S. to Xtant Medical Holdings, Inc. ("Xtant") for $5.0 million. The sale will be effectuated through the chapter 11 proceedings initiated by the Company and certain o
Company to showcase its upgraded HOLO Portal™ Surgical Guidance System and key products in its hardware spine and biologics portfolio DEERFIELD, Ill., May 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced today that it will be exhibiting at ISASS 2023 – the 23rd Annual Conference – sponsored by the International Society for Spine Surgery ("ISASS") and Medical Education Resources. This three-day event will take place June 1-3, 2023 at the Marriott Marquis in San Francisco, CA. The International Society for the Advancement of Spine Surgery i
Craig Hallum downgraded Surgalign Holdings from Buy to Hold and set a new price target of $1.50
BTIG Research initiated coverage of Surgalign Holdings with a rating of Buy and set a new price target of $4.00
BTIG Research initiated coverage of Surgalign with a rating of Buy
Gainers Baudax Bio (NASDAQ:BXRX) shares increased by 130.7% to $1.2 during Friday's regular session. Trading volume for this security as of 13:37 EST is 93.9 million, which is 10027.5% of its average full-day volume over the last 100 days. The company's market cap stands at $7.2 million. CymaBay Therapeutics (NASDAQ:CBAY) stock increased by 41.61% to $11.1. The current volume of 13.9 million shares is 855.6% of CymaBay Therapeutics's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $1.0 billion. Renalytix (NASDAQ:RNLX) stock increased by 41.14% to $2.92. Trading volume for this security as of 13:37 EST is 29.7 m
Gainers Addentax Group Corp. (NASDAQ:ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) surged 40% to $10.97. Cyteir Therapeutics, Inc. (NASDAQ:CYT) shares gained 38% to $2.6487. Cyteir Therapeutics reported discontinuation of CYT-0851 development program and planned liquidation and dissolution. TOP Financial Group Limited (NASDAQ:TOP) shares gained 32.2% to $10.31 after the company reported FY23 financial results. Renalytix Plc (NASDAQ:RNLX) shares jumped 31% to $2.66 after the company received FDA De Novo marketing autho
Gainers Renalytix (NASDAQ:RNLX) shares moved upwards by 38.6% to $2.87 during Friday's pre-market session. The company's market cap stands at $134.5 million. Cyteir Therapeutics (NASDAQ:CYT) stock rose 28.12% to $2.46. The market value of their outstanding shares is at $87.3 million. CymaBay Therapeutics (NASDAQ:CBAY) stock increased by 22.7% to $9.62. The company's market cap stands at $938.0 million. CytomX Therapeutics (NASDAQ:CTMX) stock rose 21.98% to $1.72. The company's market cap stands at $114.1 million. Baudax Bio (NASDAQ:BXRX) stock increased by 21.14% to $0.63. The market value of their outstanding shares is at $3.8 million. Alvotech (NASDAQ:ALVO) stock rose 11.59% to $7.7.
SC 13G/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13G - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13D/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)